FCGR3A and cancer: BiMEs simultaneously bind tumor-associated antigens (TAAs) on cancer cells and activating receptors on macrophages, such as Fcγ receptors (FcγRI, FcγRIIa, and FcγRIIIa), to induce antibody-dependent cellular phagocytosis (ADCP) and cytokine secretion.